JP-163-16 is a RelA/p65 PROTAC degrader. It selectively reduces the expression of RelA/p65 in cells via a proteasome-dependent mechanism. JP-163-16 induces apoptosis by inhibiting the NF-kappaB signaling pathway. This compound is applicable for research on RelA/p65-dependent tumors, such as chronic lymphocytic leukemia (CLL).
Target-Kategorie:
Apoptosis|||PROTACs|||NF-kappaB
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
